EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease

Corry D Bondi, Hannah L Hartman, Brittney M Rush, Roderick J Tan iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25094987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Corry D Bondi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, PA 152671, USA. Hauptthemen laut MEDLINE: Chemokine CCL2, Podocytes, Doxorubicin, Angiotensin II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Investigating the role of podocytes in proteinuric disease is imperative to address the increasing global burden of chronic kidney disease (CKD). Studies strongly implicate increased levels of monocyte chemoattractant protein-1 (MCP-1/CCL2) in proteinuric CKD. Since podocytes express the receptor for MCP-1 (i.e., CCR2), we hypothesized that podocyte-specific MCP-1 production in response to stimuli could activate its receptor in an autocrine manner, leading to further podocyte injury. To test this hypothesis, we generated podocyte-specific MCP-1 knockout mice (Podo-Mcp-1fl/fl) and exposed them to proteinuric injury induced by either angiotensin II (Ang II; 1.5 mg/kg/d, osmotic minipump) or Adriamycin (Adr; 18 mg/kg, intravenous bolus). At baseline, there were no between-group differences in body weight, histology, albuminuria, and podocyte markers. After 28 days, there were no between-group differences in survival, change in body weight, albuminuria, kidney function, glomerular injury, and tubulointerstitial fibrosis. The lack of protection in the knockout mice suggests that podocyte-specific MCP-1 production is not a major contributor to either Ang II- or Adr-induced glomerular disease, implicating that another cell type is the source of pathogenic MCP-1 production in CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CCL2PodocytesDoxorubicinAngiotensin IIMice, KnockoutAnimalsMiceMaleRenal Insufficiency, ChronicGene DeletionDisease Models, Animal

Stichwörter der Autor:innen

CCL2CCR2chronic kidney diseaseglomerular injurypodocyteproteinuria

Substanzen

Chemokine CCL2DoxorubicinAngiotensin IICcl2 protein, mouse

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh, Pittsburgh, PA 152671, USA.

ORCID-Profile: Roderick J Tan

Förderung

  • NIDDK NIH HHS
  • BLRD VA
  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • American Heart Association
  • Department of Veterans Affairs Merit Award
  • National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Bondi, C. D., Hartman, H. L., Rush, B. M., & Tan, R. J. (2024). Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094987

Vancouver

Bondi CD, Hartman HL, Rush BM, Tan RJ. Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094987

BibTeX
@article{Bondi2024,
  author = {Bondi, Corry D and Hartman, Hannah L and Rush, Brittney M and Tan, Roderick J},
  title = {Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25094987}
}
Kostenlos starten →